

COOPERATION TREATMENT COOPERATION TREATMENT COOPERATION TREATMENT 2005

EC'D 0 4 JAN 2005

WIPO

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70) 10/541604

Applicant's or agent's file reference	FOR FURTHER ACTI	ON	Co. F POTIDE 1114		
P 65123	- CALL CHARLEST ACT		See Form PCT/IPEA/416		
International application No. PCT/EP2004/000299	International filing date (day 16.01.2004	/month/year)	Priority date (day/month/year) 17.01.2003		
International Patent Classification (IPC) or	national classification and IPC				
C07D495/04, C07D295/04					
Applicant					
KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO et al.					
This report is the international pr Authority under Article 35 and tra	eliminary examination report	t, established by this	International Preliminary Examining		
	·				
3. This report is also accompanied by ANNEXES, comprising:					
a. 🗆 sent to the applicant and	· · · · · · · · · · · · · · · · · · ·				
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).					
☐ sheets which superse	de earlier sheets, but which	this Authority considion as filed, as indica	lers contain an amendment that goes ated in item 4 of Box No. I and the		
b. 🛘 (sent to the International I	Bureau only) a total of (indica	ate type and number	of electronic carrier(s)) , containing a		
sequence iisting and/or ta	bles related thereto, in comp Listing (see Section 802 of	ulter readable form o	inly as indicated in the Supplemental		
box relating to ocquerice	Listing (see Section 602 of	trie Administrative in	istructions).		
4. This report contains indications re	elating to the following items				
☑ Box No. I Basis of the op	nion				
☐ Box No. II Priority					
☐ Box No. III Non-establishm	ent of opinion with regard to	novelty, inventive st	ep and industrial applicability		
Box No. IV Lack of unity of	invention		•		
applicability; cit	ement under Article 35(2) wit ations and explanations sup	h regard to novelty, i porting such stateme	nventive step or industrial		
☐ Box No. VI Certain docume	ents cited				
	in the international application	-,,			
☐ Box No. VIII Certain observa	itions on the international ap	plication			
Date of submission of the demand		e of completion of this	report		
		·			
17.08.2004		.12.2004			
Name and mailing address of the international preliminary examining authority:		Authorized Officer			
European Patent Office			September 19		
D-80298 Munich Tel. +49 89 2399 - 0 Tx: 5236	56 epmu d	ston, E			
Fax: +49 89 2399 - 4465	· '	ephone No. +49 89 239	9-8229		



International application No. PCT/EP2004/000299

	Box	No. I Basis of the report
1.	With filed,	regard to the language , this report is based on the international application in the language in which it was unless otherwise indicated under this item.
	ν	This report is based on translations from the original language into the following language, which is the language of a translation furnished for the purposes of: international search (under Rules 12.3 and 23.1(b))
		publication of the international application (under Rule 12.4) international preliminary examination (under Rules 55.2 and/or 55.3)
2.	have	regard to the elements* of the international application, this report is based on (replacement sheets which been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this t as "originally filed" and are not annexed to this report):
	Desci	iption, Pages
	1-18	as originally filed
	Claim	s, Numbers
	1-10	as originally filed
	□ а	sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing
3.		he amendments have resulted in the cancellation of:
		I the description, pages I the claims, Nos.
		the drawings, sheets/figs
	L	the sequence listing <i>(specify)</i> : any table(s) related to sequence listing <i>(specify)</i> :
4.	had n	his report has been established as if (some of) the amendments annexed to this report and listed below ot been made, since they have been considered to go beyond the disclosure as filed, as indicated in the emental Box (Rule 70.2(c)).
		the description, pages the claims, Nos.
		the claims, Nos. I the drawings, sheets/figs
		the sequence listing (specify): any table(s) related to sequence listing (specify):
	* I	f item 4 applies, some or all of these sheets may be marked "superseded."



International application No. PCT/EP2004/000299

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N) Yes: Claims 1-10

No: Claims

Inventive step (IS) Yes: Claims 1-10

No: Claims

Industrial applicability (IA) Yes: Claims 1-10

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet



INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)



PCT/EP2004/000299

To section V

The following documents were cited in the search report and were considered for the examination of the present application:

D1: GB-A-1 533 235 (LILLY INDUSTRIES LTD) 22 November 1978

D2: EP-A-0 454 436 (LILLY INDUSTRIES LTD) 30 October 1991

D3: CALLIGARO, D.O. ET AL.: "The Synthesis and Biological Activity of some known and Putative Metabolites of the Atypical Antipsychotic Agent Olanzapine (LY170053)" BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 7, no. 1, 1997, pages 25-30,

The present application deals with a process for the preparation of the CNS-active compound Olanzapine (claims 1-5); furthermore compounds useful as intermediates in this process are claimed (claims 6-10).

Documents D1 (page 10) and D2 (claim 7) anticipate processes which are characterized by a cyclization reaction starting from a phenyl/thienyl amino precursor. In contrast to this the presently claimed process starts from a benzodiazepine intermediate which is subjected to a cyclization reaction using sulfur thus resulting in the formation of the annellated thiophene heterocycle.

Document D3 discloses some derivative sof Olanzapine which are not interfering with claims 6-10.

In view of the aforementioned differences novelty is acknowledged for claims 1-10 (Art. 33(2) PCT).

The description contains data which show that the claimed process results in the formation of the desired target molecule in good yield and purity. Thus the involvement of an inventive step is acknowledged (Art. 33(3) PCT).